Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other degenerative diseases, today announced Casey Lynch, the company’s chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.
A live webcast of the corporate presentation will be accessible at the Investor Calendar page under the News & Events heading of the Cortexyme investor site (ir.cortexyme.com). The webcast will be archived at that location for 90 days.
In addition to the corporate presentation, Ms. Lynch will participate in a plenary session at the Forum, “Advances in Alzheimer’s & Other Cognitive Disorders,” earlier in the day. This event will feature brief presentations from a panel of neuroscience drug development experts followed by a roundtable discussion moderated by co-chairs Christian Jung, Partner at the Dementia Discovery Fund, and Sumant Kulkarni, Managing Director of Biotechnology Equity Research at Canaccord Genuity LLC.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s disease and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. The company’s lead investigational medicine, COR388, is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in patients with mild to moderate Alzheimer’s. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the final prospectus related to Cortexyme’s initial public offering filed with the Securities and Exchange Commission on May 9, 2019 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.
For Cortexyme, Inc.
Source: Cortexyme, Inc.